Red cell transfusions are part of the routine supportive care following haematopoietic stem cell transplantation. There is increasing evidence from randomized controlled trials demonstrating that restrictive transfusion thresholds are equivalent to liberal thresholds in other patient populations. However, given the lack of patient-centred outcomes and the longer transfusion support required for patients with haematologic malignancies, the results of these trials may not be generalizable to haematology-oncology patients. In the recently completed multicentre TRIST trial, we randomized 300 patients requiring an autologous or allogeneic haematopoietic stem cell transplantation to either a restrictive (haemoglobin threshold <70 g/l) or liberal (haemoglobin threshold <90 g/l) red cell transfusion strategy. Our primary outcome was health-related quality of life measured by FACT-BMT through day 100 post-transplant. The median number of red cell units transfused was lower in the restrictive strategy group (2 vs. 4). The FACT-BMT total score was higher at all time points for patients in the restrictive transfusion group including at baseline (109 vs. 103) and at 100 days (116Á3 vs. 109Á2). After adjustment for baseline, the FACT-BMT score at day 100 in the restrictive group was statistically non-inferior to the liberal group (P < 0Á0001). There were no significant differences between the two groups for any other clinical outcomes. Based on the results of the TRIST trial, a restrictive haemoglobin threshold of 70 g/l should become standard practice in haematopoietic stem cell transplant patients, and, given the lack of other clinical studies, all other haematology-oncology inpatients.
Introduction
Red cell transfusions have been a life-saving medical procedure since the introduction into routine medical practice in the first half of the twentieth century. Until very recently, red cell utilization has consistently increased as red cells were a critical supportive therapy for patients undergoing increasingly complex and intensive surgical and medical therapies [1] . In patients with malignancies, red cell transfusions are commonly given during active chemotherapy treatment as supportive treatment. Patients undergoing haematopoietic stem cell transplant receive the most intensive chemotherapy, and, as a result, red cell transfusions are required by most patients in the immediate post-transplant period [2] . Indeed, patients with all malignancies including those undergoing haematopoietic stem cell transplant represent an important proportion of all red cell utilization. While there have been a number of studies, demonstrating the safety and efficacy of restrictive red cell transfusion thresholds in various clinical settings, there is relative paucity of data for red cell transfusions in patients with malignancies, and specifically in patients undergoing haematologic malignancies [3] . In this article, we will review the recent clinical trials and guidelines for red cell transfusion, and the significance of these findings for patients with malignancies, particularly for patients undergoing haematopoietic stem cell transplant.
Rationale for red cell transfusions
The primary purpose of the red cell is to deliver oxygen (O 2 ) to the tissues. All but a small amount of the arterial oxygen content of the blood is bound to the haemoglobin in the red cell. The O 2 delivery is dependent on both the oxygen content of the blood and the cardiac output. As the haemoglobin levels decrease, the oxygen content of the blood declines, but there are compensatory cardiac mechanisms to increase the cardiac output [4] . In a normal physiologic state, the oxygen delivery exceeds the oxygen consumption by a factor of three-fourfold. As the haemoglobin declines, the oxygen extraction ratio increases, but even at a haemoglobin level of 100 g/l, the oxygen delivery remains two times higher than O 2 consumption. During the haemoglobin ranges for which a red cell transfusion is usually given, the oxygen consumption remains constant and is O 2 delivery independent. Thus, a red cell transfusion will increase the haemoglobin concentration and oxygen deliver but, in normal physiologic conditions, would not be expected to increase O 2 consumption. As the haemoglobin level continues to decline, the oxygen extraction ratio continues to increase, and, at a specific point, further oxygen extraction is not possible and O 2 consumption becomes dependent on oxygen delivery. Below this critical haemoglobin level, adverse clinical effects would be expected as patients have to rely on anaerobic metabolism. The haemoglobin level associated with critical O 2 delivery varies but in healthy volunteers [5] , and appears to be below 50 g/l, which is certainly well below any of the restrictive red cell transfusion thresholds studied in North America or Europe. The haemoglobin level associated with critical O 2 delivery will certainly be higher in patients with underlying medical conditions that impair compensatory mechanisms to increase either cardiac output or O 2 extraction. Clearly, any red cell transfusion threshold should aim to keep patients well above the level of critical O 2 delivery to avoid adverse clinical outcomes. However, as haemoglobin levels fall but still remain above the critical O 2 delivery, there could be clinically significant impacts on patient-centred outcomes such as quality of life. For patients who require prolonged or chronic red cell transfusion support, the effect of red cell transfusions on patient-centred outcomes such as quality of life can be important.
Current clinical evidence for restrictive red cell transfusion thresholds
The first large randomized clinical trial to compare two different red cell transfusion thresholds was the Transfusion in Critical Care (TRICC) [6] . The TRICC trial randomized 838 non-bleeding critical care patients in 22 Canadian intensive care units to a restrictive red cell transfusion threshold of 70 g/l or a liberal red cell transfusion threshold of 100 g/l. For the primary outcome of 30-day mortality, there was a non-significant trend for decreased mortality (19Á7% vs. 23Á3%, P = 0Á11), favoring patients in the restrictive transfusion group. The hospital mortality rates were significantly lower in the restrictive transfusion group (22Á2% vs. 28Á1%, P = 0Á05). The authors concluded that 'a restrictive strategy of red cell transfusion is at least as effective and possibly superior to a liberal transfusion strategy in critically ill patients' [7] . The results of this trial introduced a potential paradigm shift in that red cell transfusions, which were widely considered a life-saving therapy, might now be considered potentially harmful.
Following the publication of the TRICC trial, there was clearly a need for follow-up studies not only to confirm the groundbreaking findings, but also to determine whether the findings were generalizable to other patient groups. As the TRICC trial included only acutely ill critical care patients, other patient groups who are frequent recipients of red cell transfusions would not necessarily be expected to have similar outcomes following a restrictive transfusion strategy. Patients who are not intubated and sedated may not have similar tolerance for lower haemoglobin levels as critically ill patients and the mechanisms that potentially contributed to increased mortality associated with higher red cell transfusion burdens may not have an effect in non-critically ill patients. Among frequently transfused patient groups, haematology-oncology patients are arguably the most different from the patients included in the TRICC study.
In the two decades since the publication of the TRICC trial, there have been a large number of studies examining the effects of restrictive vs. liberal red cell transfusion thresholds. A recent Cochrane review by Carson et al. identified 31 randomized clinical trials that evaluated a restrictive red cell transfusion strategy [7] . The results of the meta-analysis for 30-day mortality, which included more than 12 000 patients, did not show any differences between restrictive transfusion strategies and liberal transfusion strategies; the relative risk was 0Á97 (95% CI: 0Á81-1Á16). Overall the restrictive transfusion strategy reduced the risk of receiving a red cell transfusion by 43%. No differences were observed in any other outcomes including cardiac events, stroke, infection or thromboembolism between patients randomized to a restrictive or liberal red cell transfusion strategy.
Importantly, these clinical trials have focused on specific patient groups: orthopaedic surgery (10 trials), critical illness (6 trials), cardiac surgery (5 trials), trauma and acute blood loss (2 trials), acute coronary syndrome (2 trials) and acute leukaemia/haematologic malignancies (2 trials) [8] . In each of these subgroups, there were no differences in the reported outcomes for patients receiving a restrictive red cell transfusion strategy. For some subgroups, the number of participants was large and, as a result, the point estimate for the relative risk was close to 1 and the 95% confidence interval were relatively narrow (e.g. cardiac surgery RR: 1Á18, 95% CI: (0Á77-1Á81) [7] . For the subgroup of haematologic malignancy, which is arguably the most distinct from the other populations, the two trials included only a small number of patients (n = 149) and the risk ratio for 30-day mortality was 0Á37 with a wide 95% confidence interval (0Á07-1Á95) [7] .
The first of the two randomized controlled trials comparing red cell transfusion thresholds was a pilot trial comparing a red cell transfusion threshold of 80 g/l and 120 g/l [8] . The primary purpose of this study was to determine the feasibility of a large clinical trial examining the effect of haemoglobin concentrations on bleeding risk in thrombocytopenic patients with acute leukaemia or undergoing a haematopoietic transplant. There was no difference in rates of clinically significant bleeding, but, not surprisingly, the overall transfusions rates were significantly higher with the liberal red cell transfusion threshold (relative risk 1Á56, 95% CI: 1Á16-2Á10). Mortality was lower in the restrictive arm (1 vs. 2) [7] . In the second trial, DeZern et al. randomized patients receiving induction therapy to a red cell transfusion threshold of 70 g/l or 80 g/l [9] . Of note, the liberal transfusion in this pilot trial used the same transfusion threshold as the restrictive transfusion strategy in the previous trial. A total of 90 patients were enrolled, and the patients in the restrictive transfusion group received fewer red cell units transfused (8Á0 vs. 11Á7 units/patient, P = 0Á0003). The number of deaths was lower in the restrictive arm (1 vs. 2). Together, these trials demonstrate that more restrictive red cell transfusion thresholds reduce the number of units transfused in patients with haematologic malignancies. Unfortunately, the number of outcome events in these studies was small and not sufficient to determine whether there were any important differences between the restrictive and liberal red cell transfusion groups. Additionally, the trial by Webert used a very high liberal transfusion threshold of 120 g/l; therefore, any adverse outcomes may have been caused by the very high haemoglobin threshold in this trial [8] . Indeed, a paediatric trial comparing red cell transfusion thresholds of 80 g/l and 120 g/l was stopped after only six patients due to the an excessive number of cases of veno-occlusive disease with the higher transfusion threshold [10] . In the second trial by Dezern et al., the difference in the transfusion threshold in the restrictive arm was only 10 g/l lower than the liberal arm threshold, which may not be a sufficiently large difference in haemoglobin to affect clinical outcomes [9] .
The one additional study comparing a restrictive and liberal red cell transfusion threshold in adult patients was a retrospective study that compared the outcomes in AML patients from two hospitals with different red cell transfusion thresholds who were both participating in the same prospective randomized clinical trial [11] . The restrictive site used age-dependent red cell transfusion thresholds of varying from 72 g/l to 88 g/l, while the liberal site used a red cell transfusion threshold of 96 g/l. Overall, there were lower haemoglobin levels (mean haemoglobin difference 13 g/l, P < 0Á05) and an 11% reduction in red cell units transfused in patients treated with the restrictive red cell transfusion policy. There were no differences in any other outcomes measured including bleeding, remission status or mortality.
Outcomes in red cell transfusion threshold trials
The primary outcome in most clinical trials examining red cell transfusion thresholds has been mortality (either alone or combined with other serious morbidity). For example, the TRICC trial had a primary outcome of 30-day mortality [7] . While mortality is clearly an important clinical outcome, in conditions with low overall rates of mortality, it may not be feasible to power clinical trials for this outcome. Additionally, as the results of clinical trials performed to date have not shown a difference in mortality, then it becomes important to consider other clinical outcomes. Some clinical trials used composite outcomes combining mortality with other serious comorbidity. The TRICS III trial in cardiac surgery [12] used a composite outcome including mortality and other serious morbidities as the primary outcome. In the randomized clinical trials performed to date, there is no evidence that clearly demonstrates that different red cell transfusion strategies change these composite outcomes or any of the individual components [7] .
Given the lack of a clear effect by different red cell transfusion thresholds on mortality and major morbidity, functional outcomes and health-related quality of life become important outcomes to consider in trials evaluating red cell transfusion thresholds. To date, only four clinical trials in orthopaedic surgery have included functional outcomes as a primary outcome. The most notable is the FOCUS trial which had a combined primary outcome of death or ability to walk 10 feet at 60 days post-hip fracture surgery [13] . In patients with haematologic malignancies, health-related quality of life is an especially important outcome given the more prolonged period of transfusion support. The two prospective randomized controlled trials of patients with haematologic malignancies [8, 9] were both pilot studies and therefore focused on feasibility outcomes. They were not powered to detect differences in mortality or other major morbidities, and they did not evaluate functional or quality-of-life outcomes.
The Transfusion of Red Cells in Haematopoietic Stem Cell Transplantation (TRIST) study
Given the lack of data from randomized clinical trials in patients with haematologic malignancies, we undertook a prospective trial to evaluate a restrictive transfusion threshold as compared to a liberal transfusion threshold in patients undergoing haematopoietic stem cell transplantation (HSCT) [14] . This was an open-labelled multicentre parallel design non-inferiority randomized controlled trial. A vanguard design was used such that patients enrolled in the pilot trial were rolled over into the phase 3 trial.
Four Canadian adult haematopoietic stem cell transplant centres participated in the full study. Both allogeneic and autologous stem cell transplant patients were enrolled in the study. Our inclusion criteria were: (1) 18 years of age or older and (2) undergoing autologous or allogeneic haematopoietic stem cell transplantation for any haematologic malignancy. We excluded patients who were: (1) pregnant or lactating at the time of enrolment, (2) already received red cell transfusion after HSCT but prior to enrolment, (3) unable/unwilling to provide informed consent and (4) patients receiving HSCT for non-malignancies.
Patients were randomized to either a liberal or restrictive red cell transfusion strategy based on the morning bloodwork results. The transfusion strategy was carried out from Day 0 (day of stem cell infusion) to Day 100. Patients in the liberal transfusion strategy received 2 units of red cells when the daily haemoglobin level was less than 90 g/l. In the restrictive transfusion strategy, patients received 2 units of red cells when the haemoglobin was less than 70 g/l. These thresholds were chosen as 70 g/l and the lower restrictive threshold used in clinical trials in other patient groups. The liberal threshold of 90 g/l was chosen as a review of data at our centre demonstrated that HSCT patients were frequently transfused at a haemoglobin level greater than 80 g/l (similar findings were also confirmed by other centres), and this threshold would provide an adequate difference between the two groups [14] .
For our pilot study, the primary outcomes were feasibility. After evaluating the blinded (combined) results from the pilot study, we determined that, given the low mortality rates post-HSCT, the most important outcome was quality of life. For the primary outcome, we chose healthrelated quality of life measured by the FACT-BMT [15] scale at Day 100. The FACT-BMT is a validated self-report Fig. 1 Box plot for FACT-BMT total scores for patients in the liberal red cell transfusion group (<90 g/l) and the restrictive red cell transfusion group (<70 g/l) [16] .
questionnaire that utilizes a five-point Likert scale in five domains: physical well-being, functional well-being, social/family well-being, emotional well-being, and the BMT subscale that includes additional items specifically designed to test quality of life and symptoms specific to transplant patient is the most commonly used and validated measure in HSCT.
Our secondary outcomes included other quality-of-life scales, transplant-related mortality, length of hospital stay, ICU admissions, acute graft-versus-host disease, serious infections, transfusion requirements, bleeding, adverse transfusion reactions, and sinusoidal obstruction (veno-occlusive) syndrome.
The sample size was 300 patients (150 autologous HSCT and 150 allogeneic HSCT). The non-inferiority margin was a 12% absolute difference between groups in FACT-BMT score relative to baseline. The sample size provided a power of 80% to reject inferiority assuming the true difference between the groups was 6%.
In our preliminary analysis [16] , the difference in the overall mean pre-transfusion haemoglobin per patient between the two groups was 13Á7 g/l (standard deviation 9Á8 g/l). The median number of RBC units transfused was 2 (interquartile range 2-6) in the restrictive transfusion group and 4 (interquartile range 2-6) in the liberal transfusion group. Overall, the number of red cell units transfused decreased by 46% in the restrictive transfusion group. The FACT-BMT total score was higher at all time points for patients in the restrictive transfusion group including at baseline (109 vs. 103) and at 100 days (116Á3 vs. 109Á2). For the primary outcome of the FACT-BMT score at 100 days post-HSCT, non-inferiority in the restrictive red cell transfusion group was demonstrated. The estimated difference in ratios between groups was À1Á64% (95% confidence interval, À0Á07 to 0Á04; P = 0Á0001 for non-inferiority). Statistical non-inferiority was detected between the liberal and the restrictive groups at all time points (Days 7, 14, 28, 60 and 100) for both the FACT-BMT and FACT-Anemia scores (Fig. 1 ). There were no statistical differences in any of the secondary outcomes including bleeding, mortality and infection rates between the restrictive and liberal transfusion groups. With respect to bleeding, the rates of WHO grade 1, 2 or 3 bleeding were similar when assessed at days 14, 28 and 100. No grade 4 bleeds occurred in the trial, and there was no difference in platelet transfusion requirements between the restrictive and liberal arms of the study (median of two transfusions in each group).
Conclusion
A restrictive red cell transfusion strategy was first investigated in a large randomized controlled trial in critical care patients almost 20 years ago [7] . Since that time, a large number of randomized controlled trials examined differences between restrictive and liberal red cell transfusion strategies in different patient groups [8] . However, there has been a lack of clinical trials evaluating a restrictive transfusion strategy in haematology-oncology patients [3] . The TRIST trial represents the first large randomized controlled trial to evaluate a restrictive transfusion strategy in this patient group. Importantly, our study was designed to detect differences in quality of life, which is an important outcome in patients requiring prolonged red cell transfusion support. Our study of patients undergoing haematopoietic stem cell transplant demonstrated non-inferiority of a restrictive red cell transfusion strategy on quality of life. There were no significant differences in any other outcomes between the restrictive and liberal transfusion strategies, and the restrictive transfusion strategy significantly reduced red cell utilization. Based on these findings, a restrictive red cell transfusion strategy with a haemoglobin threshold of 70 g/l should be considered the standard of care for patients undergoing haematopoietic stem cell transplantation. In the absence of additional evidence, the results of this trial can also be applied to inpatients with haematologic malignancies or non-haematological cancers.
